Robert Michael will replace former CEO Richard Gonzalez, marking the official end to Gonzalez’s long reign at the pharma ...

AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...

AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor ...

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

Richard Gonzalez is retiring as chairman of AbbVie. "AbbVie Names CEO Robert Michael Chairman as Richard Gonzales Retires," at 8:20 a.m. ET, misspelled his name as Gonzales in the headline and article ...

NORTH CHICAGO, Ill. - Pharmaceutical (TADAWUL:2070) giant AbbVie (NYSE:ABBV), a $339 billion market cap company with a strong financial health rating according to InvestingPro, and biotech firm ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier.

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier.

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...

AbbVie and Xilio Therapeutics have inked a collaboration and option-to-license agreement potentially worth more than $2 billion to clinical-stage biotechnology company Xilio.